Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of AR1001 in early Alzheimer's disease
CTR20244348Phase 3Active
- Sponsor
- 不适用/ 博纳西亚（合肥）医药科技有限公司
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mirodenafil in Alzheimer's disease (AD), sponsored by 不适用/ 博纳西亚（合肥）医药科技有限公司. Started Dec 2024; status: active.
02
Drugs
mirodenafil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20244348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244348.